Kjell Simonsson
Plus aucun poste en cours
Profil
Kjell Simonsson worked as a Director at Masimo Sweden AB from 2002 to 2009.
He was also the Managing Director at KI Management AB from 1999 to 2009.
Additionally, he worked as a Director at Independent Pharmaceutica AB.
Anciens postes connus de Kjell Simonsson
| Sociétés | Poste | Fin |
|---|---|---|
KI Management AB
 KI Management AB Investment ManagersFinance KI Management AB (KIM) is a venture capital investment firm located in Stockholm, on the campus of the Karolinska Institute. They are the investment advisor and manager of the Karolinska Investment Fund KB (KIF). The fund was established in 1999 by the Karolinska Institute and Alecta, a Nordic pension plan. KIM has a partnership agreement with Karolinska Innovations AB, a technology transfer entity of the Karolinska Institute. The Karolinska Institute, founded in 1810, has a medical focus and is responsible for selecting the winner of the Nobel Prize in Physiology or Medicine. | President | 31/12/2009 |
Independent Pharmaceutica AB
 Independent Pharmaceutica AB Medical DistributorsDistribution Services Independent Pharmaceutica AB is a privately owned company. The major owners are Karolinska Investment Fund, LH Advisory, Sandin &Co and The Foundation for Baltic and East European Studies (Östersjöstiftelsen). Independent Pharmaceutica aims to provide pharmacological solutions for treatment of nicotine addiction. The company is spun out of research from the Karolinska Institutet in Stockholm, Sweden. Tobacco use is the leading preventable cause of morbidity and premature death in the world.Currently over 1.2 billion people smoke worldwide and the number of annual deaths from tobacco-related diseases is over 4 million and rising. The costs for society are huge. With the new vaccine Niccine® against nicotine addiction, the health condition of millions of patients is expected to be improved. | Directeur/Membre du Conseil | - |
Masimo Sweden AB
 Masimo Sweden AB Electronic Equipment/InstrumentsElectronic Technology Masimo Sweden AB develops and markets ultra-small gas monitoring probes. It sells mobile multigas analyzers that enable to measure respiratory gases in any clinical application. The firms products include IRMA Mainstream Analyzers, ISA Sidestream Analyzers, Nomoline Sampling Lines, EMMA Capnometers, and EMMA Carnograph. The company was founded by Anders Eckerbom and Robert Zyzanski in 1989 and is headquartered in Danderyd, Sweden. | Directeur/Membre du Conseil | 17/01/2011 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Masimo Sweden AB
Masimo Sweden AB Electronic Equipment/InstrumentsElectronic Technology Masimo Sweden AB develops and markets ultra-small gas monitoring probes. It sells mobile multigas analyzers that enable to measure respiratory gases in any clinical application. The firms products include IRMA Mainstream Analyzers, ISA Sidestream Analyzers, Nomoline Sampling Lines, EMMA Capnometers, and EMMA Carnograph. The company was founded by Anders Eckerbom and Robert Zyzanski in 1989 and is headquartered in Danderyd, Sweden. | Electronic Technology |
KI Management AB
KI Management AB Investment ManagersFinance KI Management AB (KIM) is a venture capital investment firm located in Stockholm, on the campus of the Karolinska Institute. They are the investment advisor and manager of the Karolinska Investment Fund KB (KIF). The fund was established in 1999 by the Karolinska Institute and Alecta, a Nordic pension plan. KIM has a partnership agreement with Karolinska Innovations AB, a technology transfer entity of the Karolinska Institute. The Karolinska Institute, founded in 1810, has a medical focus and is responsible for selecting the winner of the Nobel Prize in Physiology or Medicine. | Finance |
Independent Pharmaceutica AB
Independent Pharmaceutica AB Medical DistributorsDistribution Services Independent Pharmaceutica AB is a privately owned company. The major owners are Karolinska Investment Fund, LH Advisory, Sandin &Co and The Foundation for Baltic and East European Studies (Östersjöstiftelsen). Independent Pharmaceutica aims to provide pharmacological solutions for treatment of nicotine addiction. The company is spun out of research from the Karolinska Institutet in Stockholm, Sweden. Tobacco use is the leading preventable cause of morbidity and premature death in the world.Currently over 1.2 billion people smoke worldwide and the number of annual deaths from tobacco-related diseases is over 4 million and rising. The costs for society are huge. With the new vaccine Niccine® against nicotine addiction, the health condition of millions of patients is expected to be improved. | Distribution Services |
